miR‑212 regulated by HIF‑1α promotes the progression of pancreatic cancer

Yue, Hui; Liu, Lin; Song, Zhenguo

doi:10.3892/etm.2019.7213

Cited by 17 publications

(11 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similarly, the present study revealed that miR-519 was modulated by hypoxia. Certain research groups have demonstrated that various miRNAs, including miR-212 and miR-224, promote pancreatic cancer progression via hypoxia-inducible factor 1α (27,28). By contrast, the present study revealed that miR-519 inhibited the tumorigenesis of pancreatic cancer cells, in accordance with prior conclusions (29,30).…”

Section: Discussionsupporting

confidence: 87%

MicroRNA‑519 inhibits hypoxia‑induced tumorigenesis of pancreatic cancer by regulating immune checkpoint PD‑L1

et al. 2019

View full text Add to dashboard Cite

Pancreatic cancer is highly prevalent and exhibits a high incidence and mortality rate. Hypoxia contributes to tumorigenesis and the progression of pancreatic cancer. To the best of our knowledge, the role of microRNA (miR)-519 has not been investigated in hypoxia-induced pancreatic cancer progression. The purpose of the present study was to elucidate the mechanism underlying miR-519-mediated regulation of pancreatic cancer progression. Reverse transcription-quantitative PCR and western blotting were performed to investigate miR-519 and programmed death ligand 1 (PD-L1) mRNA and protein levels, respectively. Additionally, a Transwell assay was performed to examine the invasiveness of PANC-1 and SW1990 cells. Cells were subsequently stained with Annexin V to determine the apoptotic rate of cells. Furthermore, bioinformatics analysis and a dual-luciferase reporter assay were performed to confirm the direct association between miR-519 and PD-L1, and a xenograft experiment was conducted to test the role of miR-519 in vivo. The results revealed that the expression levels of miR-519 in pancreatic cancer cells were reduced following hypoxia treatment. Furthermore, transfection with miR-519 mimics inhibited PANC-1 and SW1990 cell invasiveness, and induced apoptosis under hypoxic conditions. PD-L1 was also identified as a downstream target of miR-519, and rescued the miR-519 mimic-attenuated tumorigenesis of pancreatic cancer cells under hypoxic conditions. Additionally, treatment with miR-519 mimics significantly suppressed the tumor growth of PANC-1 cells. The results of the present study indicated a novel mechanism of miR-519-mediated tumorigenesis in pancreatic cancer cells under hypoxic conditions. The conclusions may be crucial for the improvement of future pancreatic cancer treatment.

show abstract

Section: Discussionsupporting

confidence: 87%

MicroRNA‑519 inhibits hypoxia‑induced tumorigenesis of pancreatic cancer by regulating immune checkpoint PD‑L1

et al. 2019

View full text Add to dashboard Cite

show abstract

“…In the current study, it has been shown the positive correlation between deregulation of miR-212 and TNM stage, lymph node metastasis, vessel invasion, size of the tumor and the overall survival time. Latest, it has been found that in hypoxic conditions miR-212 aberration was correlated with the hypoxia-inducible factor (HIF-1α) in vivo and in vitro [ 133 ]. In turn, in cervical cancer tissues and cell lines, miR-212 was found outstandingly down regulated and promoted proliferation and invasion of cancer cells.…”

Section: Discussionmentioning

confidence: 99%

Systematic review and meta-analysis of the prognostic significance of microRNAs related to metastatic and EMT process among prostate cancer patients

et al. 2021

View full text Add to dashboard Cite

The ability of tumor cells to spread from their origin place and form secondary tumor foci is determined by the epithelial–mesenchymal transition process. In epithelial tumors such as prostate cancer (PCa), the loss of intercellular interactions can be observed as a change in expression of polarity proteins. Epithelial cells acquire ability to migrate, what leads to the formation of distal metastases. In recent years, the interest in miRNA molecules as potential future treatment options has increased. In tumor microenvironment, miRNAs have the ability to regulate signal transduction pathways, where they can act as suppressors or oncogenes. MiRNAs are secreted by cancer cells, and the changes in their expression levels are closely related to a cancer progression, including epithelial–mesenchymal transition. These molecules offer new diagnostic and therapeutic possibilities. Therapeutics which make use of synthesized RNA fragments and mimic or block miRNAs affected in PCa, may lead to inhibition of tumor progression and even disease re-emission. Based on appropriate qualification criteria, we conducted a selection process to identify scientific articles describing miRNAs and their relation to epithelial–mesenchymal transition in PCa patients. The studies were published in English on Pubmed, Scopus and the Web of Science before August 08, 2019. Hazard ratios (HRs) and 95% confidence intervals (CI) as well as total Gleason score were used to assess the concordance between miRNAs and presence of metastases. A total of 13 studies were included in our meta-analysis, representing 1608 PCa patients and 15 miRNA molecules. Our study clarifies a relationship between the clinicopathological features of PCa and the aberrant expression of several miRNA as well as the complex mechanism of miRNA molecules involvement in the induction and promotion of the metastatic mechanism in PCa.

show abstract

“…A recent study reported the positive relationship between the expression of HIF-1α and miR-212 in hypoxic conditions. Mechanistically, HIF-1α binds to an HRE in the miR-212 promoter region, leading to activated miR-212 expression in PC cells, and increased miR-212 was associated with a poor clinical prognosis ( 38 ).…”

Section: Non-coding Rna and Hypoxiamentioning

confidence: 99%

Novel therapies targeting hypoxia mechanism to treat pancreatic cancer

Luo

Qiu

Zheng

et al. 2021

Chinese Journal of Cancer Research

View full text Add to dashboard Cite

Pancreatic cancer (PC) is one of the deadliest malignancies. The high mortality rate of PC largely results from delayed diagnosis and early metastasis. Therefore, identifying novel treatment targets for patients with PC is urgently required to improve survival rates. A major barrier to successful treatment of PC is the presence of a hypoxic tumor microenvironment, which is associated with poor prognosis, treatment resistance, increased invasion and metastasis. Recent studies have identified a number of novel molecules and pathways in PC cells that promote cancer cells progression under hypoxic conditions, which may provide new therapy strategies to inhibit the development and metastasis of PC. This review summarizes the latest research of hypoxia in PC and provides an overview of how the current therapies have the capacity to overcome hypoxia and improve PC patient treatment. These findings will eventually provide guidance for future PC management and clinical trials and hopefully improve the survival of patients with PC.

show abstract

miR‑212 regulated by HIF‑1α promotes the progression of pancreatic cancer

Cited by 17 publications

References 28 publications

MicroRNA‑519 inhibits hypoxia‑induced tumorigenesis of pancreatic cancer by regulating immune checkpoint PD‑L1

MicroRNA‑519 inhibits hypoxia‑induced tumorigenesis of pancreatic cancer by regulating immune checkpoint PD‑L1

Systematic review and meta-analysis of the prognostic significance of microRNAs related to metastatic and EMT process among prostate cancer patients

Novel therapies targeting hypoxia mechanism to treat pancreatic cancer

Contact Info

Product

Resources

About